$14.01
1.02[7.85%]
At close: Apr 23
$14.01
0[0.00%]
PreMarket: 4:00PM EDT
NeuroPace
(NASDAQ:NPCE)NeuroPace Stock (NASDAQ:NPCE), Analyst Ratings, Price Targets, Predictions
NeuroPace Inc has a consensus price target of $18.55, established from looking at the 32 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, JP Morgan, and Cantor Fitzgerald on March 14, 2024, March 12, 2024, and March 6, 2024. With an average price target of $18.33 between Wells Fargo, JP Morgan, and Cantor Fitzgerald, there's an implied 30.86% upside for NeuroPace Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
JP Morgan
Cantor Fitzgerald
Morgan Stanley
Leerink Partners
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for NeuroPace
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/14/2024 | NPCE | Buy Now | NeuroPace | $14.01 | 42.76% | Wells Fargo | Lawrence Biegelsen | $16 → $20 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/12/2024 | NPCE | Buy Now | NeuroPace | $14.01 | 21.34% | JP Morgan | Robbie Marcus | $9 → $17 | Maintains | Overweight | Get Alert |
| 03/06/2024 | NPCE | Buy Now | NeuroPace | $14.01 | 28.48% | Cantor Fitzgerald | Ross Osborn | $16 → $18 | Maintains | Overweight | Get Alert |
| 03/06/2024 | NPCE | Buy Now | NeuroPace | $14.01 | -7.21% | Morgan Stanley | Drew Ranieri | $9 → $13 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | NPCE | Buy Now | NeuroPace | $14.01 | 14.2% | Wells Fargo | Lawrence Biegelsen | $9 → $16 | Maintains | Equal-Weight | Get Alert |
| 01/30/2024 | NPCE | Buy Now | NeuroPace | $14.01 | 57.03% | Leerink Partners | Mike Kratky | → $22 | Initiates | → Outperform | Get Alert |
| 12/27/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -14.35% | Lake Street | Frank Takkinen | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -35.76% | Morgan Stanley | Drew Ranieri | $8 → $9 | Maintains | Equal-Weight | Get Alert |
| 11/14/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -42.9% | Morgan Stanley | Drew Ranieri | $6 → $8 | Maintains | Equal-Weight | Get Alert |
| 11/10/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -21.48% | Cantor Fitzgerald | Ross Osborn | → $11 | Initiates | → Overweight | Get Alert |
| 11/07/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -35.76% | JP Morgan | Robbie Marcus | $6 → $9 | Maintains | Overweight | Get Alert |
| 10/04/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -35.76% | Wells Fargo | Lawrence Biegelsen | $6 → $9 | Maintains | Equal-Weight | Get Alert |
| 08/24/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -57.17% | Morgan Stanley | Drew Ranieri | $5 → $6 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/05/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -64.31% | Morgan Stanley | Drew Ranieri | $4.5 → $5 | Maintains | Underweight | Get Alert |
| 03/03/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -67.88% | Morgan Stanley | Drew Ranieri | $2.5 → $4.5 | Maintains | Underweight | Get Alert |
| 02/22/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -28.62% | Lake Street | Frank Takkinen | → $10 | Initiates | → Buy | Get Alert |
| 01/06/2023 | NPCE | Buy Now | NeuroPace | $14.01 | -82.16% | Morgan Stanley | Drew Ranieri | $3.5 → $2.5 | Maintains | Underweight | Get Alert |
| 10/11/2022 | NPCE | Buy Now | NeuroPace | $14.01 | -75.02% | Morgan Stanley | Drew Ranieri | $5.5 → $3.5 | Maintains | Underweight | Get Alert |
| 07/15/2022 | NPCE | Buy Now | NeuroPace | $14.01 | -60.74% | Morgan Stanley | Drew Ranieri | $6 → $5.5 | Maintains | Underweight | Get Alert |
FAQ
What is the target price for NeuroPace (NPCE)?
The latest price target for NeuroPace (NASDAQ: NPCE) was reported by Wells Fargo on March 14, 2024. The analyst firm set a price target for $20.00 expecting NPCE to rise to within 12 months (a possible 42.76% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeuroPace (NPCE)?
The latest analyst rating for NeuroPace (NASDAQ: NPCE) was provided by Wells Fargo, and NeuroPace upgraded their overweight rating.
When was the last upgrade for NeuroPace (NPCE)?
The last upgrade for NeuroPace Inc happened on March 14, 2024 when Wells Fargo raised their price target to $20. Wells Fargo previously had an equal-weight for NeuroPace Inc.
When was the last downgrade for NeuroPace (NPCE)?
The last downgrade for NeuroPace Inc happened on January 19, 2022 when Wells Fargo changed their price target from N/A to $11 for NeuroPace Inc.
When is the next analyst rating going to be posted or updated for NeuroPace (NPCE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroPace, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroPace was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
Is the Analyst Rating NeuroPace (NPCE) correct?
While ratings are subjective and will change, the latest NeuroPace (NPCE) rating was a upgraded with a price target of $16.00 to $20.00. The current price NeuroPace (NPCE) is trading at is $14.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.